



COMMENTARY

Open Access

# Real-time *in vivo* imaging of $p16^{INK4a}$ gene expression: a new approach to study senescence stress signaling in living animals

Naoko Ohtani\*, Kimi Yamakoshi, Akiko Takahashi, Eiji Hara\*

## Abstract

Oncogenic proliferative signals are coupled to a variety of growth inhibitory processes. In cultured primary human fibroblasts, for example, ectopic expression of oncogenic Ras or its downstream mediator initiates cellular senescence, the state of irreversible cell cycle arrest, through up-regulation of cyclin-dependent kinase (CDK) inhibitors, such as  $p16^{INK4a}$ . To date, much of our current knowledge of how human  $p16^{INK4a}$  gene expression is induced by oncogenic stimuli derives from studies undertaken in cultured primary cells. However, since human  $p16^{INK4a}$  gene expression is also induced by tissue culture-imposed stress, it remains unclear whether the induction of human  $p16^{INK4a}$  gene expression in tissue-cultured cells truly reflects an anti-cancer process or is an artifact of tissue culture-imposed stress. To eliminate any potential problems arising from tissue culture imposed stress, we have recently developed a bioluminescence imaging (BLI) system for non-invasive and real-time analysis of human  $p16^{INK4a}$  gene expression in the context of a living animal. Here, we discuss the molecular mechanisms that direct  $p16^{INK4a}$  gene expression *in vivo* and its potential for tumor suppression.

## Background

The *INK4a/ARF* gene locus encodes two distinct tumor suppressor proteins,  $p16^{INK4a}$  and ARF, whose expression enhances the growth-suppressive functions of the retinoblastoma protein (pRb) and the p53 protein, respectively[1-4]. It has been estimated that more than 70% of established human cancer cell lines lack functional  $p16^{INK4a}$  due to promoter methylation, mutation, or homozygous deletion[5-10]. In many instances the deletions affect both  $p16^{INK4a}$  and ARF, but a substantial proportion of the missense mutations exclusively affect  $p16^{INK4a}$ , suggesting that  $p16^{INK4a}$ , by itself, plays significant and non-redundant roles in tumor suppression [5-10]. Indeed, accumulating evidence suggest that the  $p16^{INK4a}$  gene acts as a sensor of oncogenic stress, its expression being up-regulated upon the detection of various potentially oncogenic stimuli, such as cumulative cell division or oncogenic Ras expression, in cultured human primary cells[11-15]. This unique feature of  $p16^{INK4a}$  gene expression, together with its ability to

induce the irreversible cell cycle arrest termed cellular senescence, raises the possibility that the  $p16^{INK4a}$  gene acts as a safe-guard against neoplasia[3,4,16-19]. However since the simple act of placing cells in tissue culture is sufficient to activate  $p16^{INK4a}$  gene expression and the levels of  $p16^{INK4a}$  gene expression vary depending on the cell culture conditions[20-23], it remains unclear whether the induction of  $p16^{INK4a}$  gene expression in cultured human primary cells truly reflects an anti-cancer process or is an artifact of tissue culture-imposed stress.

We believe that  $p16^{INK4a}$  knockout mouse is a powerful tool for elucidating the physiological roles of  $p16^{INK4a}$  gene expression *in vivo*[24,25]. A limitation of this approach, however, is the developmental or somatic compensation by the remaining  $p16^{INK4a}$  family genes ( $p15^{INK4b}$ ,  $p18^{INK4c}$  and  $p19^{INK4d}$ ) [26-28]. Moreover, the possibility of cross-species differences between human  $p16^{INK4a}$  gene expression and mouse  $p16^{INK4a}$  gene expression also complicates the interpretation of  $p16^{INK4a}$  knockout mouse data[3]. Alternative approaches are therefore needed to supplement the knockout mice studies and to assist in understanding

\* Correspondence: naoko.ohtani@jfcrr.or.jp; eiji.hara@jfcrr.or.jp  
Division of Cancer Biology, Cancer Institute, Japanese Foundation for Cancer Research (JFCR), 3-8-31, Ariake, Koto-ku, Tokyo, 135-8550, Japan

the roles and mechanisms regulating human  $p16^{INK4a}$  gene expression *in vivo*.

Bioluminescence imaging (BLI) is an emerging approach that is based on the detection of light emission from cells or tissues[29,30]. Optical imaging by bioluminescence allows a non-invasive and real-time analysis of various biological responses in living animals, such as gene expression, proteolytic processing or protein-protein interactions in living animals [31-36]. Recently, we have generated a new transgenic mouse line (*p16-luc*) expressing the fusion protein of human  $p16^{INK4a}$  and firefly luciferase under the control of human  $p16^{INK4a}$  gene regulation[37]. Using this humanized mouse model, we have recently explored the dynamics of human  $p16^{INK4a}$  gene expression in many different biological processes in living animals[37]. In this commentary, we will introduce the unique utility of BLI in advancing our understanding of the timing and hence, likely roles and mechanisms regulating  $p16^{INK4a}$  gene expression *in vivo*.

#### Real-time imaging of $p16^{INK4a}$ gene expression in living animals

In order to monitor human  $p16^{INK4a}$  gene expression as accurately as possible, we used a large genomic DNA segment of the human chromosome that contains the entire *INK4a/ARF* gene locus(Figure 1). Furthermore, this human chromosomal segment was engineered to express a fusion protein of human  $p16^{INK4a}$  and firefly luciferase without deleting any genomic DNA sequences of the *INK4a/ARF* gene locus (Figure 1). This is crucial, because BMI-1, which is a negative regulator of  $p16^{INK4a}$  gene expression[38], has been shown to bind not only to the promoter region, but also to the intron region of the  $p16^{INK4a}$  gene locus[39]. Moreover, the expression of the *p16-luc* fusion protein enables us to specify  $p16^{INK4a}$  gene expression, but not *ARF* gene expression, from this overlapping gene locus.

By monitoring and quantifying the bioluminescent signal repeatedly in the same *p16-luc* mouse throughout its entire lifespan, we were able to unveil the dynamics of human  $p16^{INK4a}$  gene expression in the aging process of the transgenic mouse (Figure 2). Importantly moreover, the bioluminescence signal levels correlated well with not only exogenous (human) but also endogenous (mouse)  $p16^{INK4a}$  gene expression, indicating that overall regulation of human  $p16^{INK4a}$  gene expression is very similar to that of mouse  $p16^{INK4a}$  gene expression, at least in mouse cells[37]. This is consistent with the previous notion that the levels of  $p16^{INK4a}$  gene expression were increased during the aging process of both rodents and primates [20,40-43]. These results illustrate the potential of the *p16-luc* mice for the analysis of  $p16^{INK4a}$  gene expression in response to oncogenic stimuli *in vivo*.


#### The response of $p16^{INK4a}$ gene expression to oncogenic stimuli *in vivo*

Although ectopic expression of oncogenic Ras initiates cellular senescence through up-regulation of  $p16^{INK4a}$  expression in cultured normal human fibroblasts [3,4,13,14,44], this is not the case in freshly isolated normal human fibroblasts [23]. It remains, therefore, unclear whether the induction of  $p16^{INK4a}$  gene expression by oncogenic Ras expression in cultured cells truly reflects an anti-cancer process or an artifact of tissue culture-imposed stress. To explore this notion in a more physiological setting rather than using the ectopic expression of oncogenic Ras in cultured cells, the *p16-luc* mice were subjected to a conventional chemically-induced skin papilloma protocol with a single dose of DMBA, followed by multiple treatments with TPA. Because this protocol induces benign skin papillomas, more than 90% of which harbor an oncogenic-mutation in the *H-ras* gene[45,46], it appears to be ideal for studying the physiological response to oncogenic mutation in the endogenous *H-ras* gene *in vivo*.

When *p16-luc* mice were treated with the DMBA/TPA protocol, benign skin papillomas began to appear after 7 weeks of treatment and continued to grow to a larger size for a further 18 weeks (early-stage papilloma). Although bioluminescent signals were hardly detectable during this time, a significant level of bioluminescent signal was induced as the papillomas stopped growing (late-stage papilloma) (Figure 3). The levels of the bioluminescent signals were well correlated with those of endogenous  $p16^{INK4a}$  expression, as well as other senescence markers such as senescence-associated (SA)-galactosidase (-gal) activity and de-phosphorylation of pRb[37], indicating that the oncogenic Ras signaling derived from the endogenous H-ras gene indeed provokes  $p16^{INK4a}$  expression, accompanied by senescence cell cycle arrest, *in vivo*. This also suggests  $p16^{INK4a}$  may play important role(s) in late papillomas, presumably preventing the malignant conversion of benign tumors. In agreement with this notion, by 30 weeks after DMBA/TPA treatment, approximately 33% of  $p16^{INK4a}$  knock-out mice (C57BL/6 background) had at least one carcinoma, compared with 5% of the wild type mice (unpublished data). These results are also consistent with a previous study showing that the tumor-free survival of DMBA-treated mice was substantially reduced in  $p16^{INK4a}$  knockout mice [47].


#### Epigenetic regulatory mechanism underlying the $p16^{INK4a}$ gene induction


Given that oncogenic mutation in the *H-ras* gene occurs immediately after DMBA treatment [45], it was puzzling that  $p16^{INK4a}$  gene expression was fully induced in the late- but not early- stage papillomas (Figure 3). Interestingly, the levels of DNMT1, which is known to repress



$p16^{INK4a}$  gene expression, were significantly increased in early-stage papilloma and subsequently reduced in late-stage papillomas [37]. Intriguingly moreover, the status of the histone 3 Lys 9 methylation (H3K9me), but not the CpG methylation around the  $p16^{INK4a}$  gene promoter, was well correlated with the levels of DNMT1 expression during the course of papilloma development [37]. These results, together with a recent observation

that DNMT1 possesses an activity to enhance H3K9 methylation through interacting with G9a, a major H3K9 mono- and di- methyltransferase [48], suggest that DNMT1 serves to counterbalance the activation of the  $p16^{INK4a}$  gene promoter mediated by oncogenic Ras during skin papilloma development. Of note, the levels of DNMT1 were initially increased by oncogenic Ras expression and subsequently reduced as cells reached






the senescence stage in cultured human primary fibroblasts[37]. Together, these results indicate that a similar mechanism is likely to be involved in the regulation of *p16<sup>INK4a</sup>* gene expression by oncogenic Ras signaling, both *in vitro* and *in vivo*.

#### DNA damage response regulates *p16<sup>INK4a</sup>* gene expression through DNMT1

It has previously been shown that oncogenic Ras signaling activates the DNMT1 gene promoter through AP1 [49]. Thus, the induction of DNMT1 expression appears to be caused by a direct effect of oncogenic Ras expression. However, it was unclear how DNMT1 is reduced in the late stage of papilloma development. Our results strongly suggest that the DNA damage response (DDR) triggered by hyper-cell proliferation [50-52] plays critical role(s) in blocking *DNMT1* gene expression, at least partly, through the elevation of the reactive oxygen species (ROS) level in late-stage papillomas [37]. Since *DNMT1* gene expression is known to be regulated by E2F [53], and E2F activity is reduced by H<sub>2</sub>O<sub>2</sub> treatment

(unpublished data), it is most likely that ROS regulate *DNMT1* expression, at least in part, through E2F. These results, together with the observation that depletion of DNMT1 causes up-regulation of *p16<sup>INK4a</sup>* gene expression in cultured human cells [54,37], indicate that DDR plays key role(s) in the induction of *p16<sup>INK4a</sup>* gene expression through blocking *DNMT1* expression in the context of Ras-induced senescence *in vivo*.

Because the p53 tumor suppressor is activated immediately after detection of DNA damage, preventing accumulation of DNA damage[55,56], it is possible that p53 might block the DDR pathway activating *p16<sup>INK4a</sup>* gene expression. To explore this idea, we again took advantage of using *p16-luc* mice, in conjunction with *p16-luc* mice lacking the *p53* gene[37]. Indeed, although bioluminescent signals were only slightly induced after treatment with doxorubicin (DXR), a DNA damaging agent, in *p16-luc* mice, this effect was dramatically enhanced by *p53* deletion, especially in highly proliferating tissues such as the thymus or small intestine[37]. Furthermore,



the DDR-pathway activating  $p16^{INK4a}$  gene expression and consequent cellular senescence was provoked naturally in the thymus of nearly all mice lacking  $p53$  gene at around 10 to 20 weeks after birth[37]. It is therefore possible that  $p16^{INK4a}$  may play a back-up tumor suppressor role in case  $p53$  is accidentally inactivated, especially in highly proliferative tissue such as the thymus.

#### A regulatory circuit between p53 and p16<sup>INK4a</sup> tumor suppressors

Our results lead to the following model, in which oncogenic Ras signaling has the potential to activate  $p16^{INK4a}$  gene expression immediately [13-15], but this effect is initially counteracted by elevation of the DNMT1 levels, which thereby causes hyper-cell proliferation. However,

since hyper-cell proliferation tends to cause DNA damage and the elevation of ROS, DNMT1 gene expression is eventually reduced by this ROS increase, leading to epigenetic de-repression of  $p16^{INK4a}$  gene expression and hence senescence cell cycle arrest (see model in Figure 4). Interestingly, moreover, this pathway is potentiated in the setting of p53 deletion, because p53 tends to prevent the proliferation of damaged cells that would cause a further accumulation of DNA damage (Figure 4) [55,56]. It is therefore most likely that  $p16^{INK4a}$  plays a back-up tumor suppressor role if p53 becomes inactivated. In agreement with this notion, it has recently been shown that the levels of  $p16^{INK4a}$  gene expression are substantially increased in the mice lacking the  $p53$

gene [57]. Moreover, over-expression of Aurora A resulted in a significant induction of p16<sup>INK4a</sup> expression in the mammary glands of p53 knock-out mice [58]. It is also worth emphasizing that p53 inactivation alone is not sufficient to fully abrogate telomere-directed cellular senescence, but the combined inactivation of p53 and p16<sup>INK4a</sup> does do so [59,60]. These results, together with our recent findings[37], help to explain why mice doubly deficient for p53 and p16<sup>INK4a</sup> exhibited an increased rate of tumor formation [61,62], and why the combination of p53 and p16<sup>INK4a</sup> loss is frequently observed in human cancer cells [63].

#### Concluding remarks

It is, however, clear that all aspects of p16<sup>INK4a</sup> regulation cannot be explained by the factors described here, and that the p16<sup>INK4a</sup> gene is subject to multiple levels of control [15,38,39,64-74]. Nonetheless, we have uncovered an unexpected link between p53 and p16<sup>INK4a</sup> gene expression[37], expanding our understanding of how p16<sup>INK4a</sup> gene expression is induced by oncogenic stimuli *in vivo*, thus opening up new possibilities for its control. Visualizing the dynamics of p16<sup>INK4a</sup> gene expression in living animals, therefore, provides a powerful tool for not only helping to resolve issues connecting *in vitro* studies, but also clarifying previously unrecognized functions of this key senescence regulator in various physiological processes *in vivo*.

#### Abbreviations used in this paper

CDK: cyclin-dependent kinase; BLI: bioluminescence imaging; DDR: DNA damage response; pRb: retinoblastoma tumor suppressor protein; DNMT1: DNA methyltransferase 1; H3K9: histone 3 Lys 9; H3K9me: histone 3 Lys 9 methylation; ROS: reactive oxygen species

#### Ethical approval

The experiments done on mice in figures 1, 2 and 3 followed the guidelines approved by the Committee for the Use and Care of Experimental Animals of the Japanese Foundation for Cancer Research.

#### Acknowledgements

We thank members of the Hara lab for helpful discussion during the preparation of this manuscript. This work was supported by grants from Ministry of Education, Science, Sports and Technology of Japan, the Mitsubishi Foundation, the Naito Foundation, the Princess Takamatsu Cancer Research Fund, the Takeda Science Foundation, Uehara memorial foundation and the Vehicle Racing Commemorative Foundation.

#### Authors' contributions

NO wrote the manuscript. KY collected the information required for this commentary article. AT collected the information required for this commentary article. EH wrote the manuscript.

#### Competing interests

The authors declare that they have no competing interests.

Received: 14 December 2009

Accepted: 14 January 2010 Published: 14 January 2010

#### References

1. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. *Nature* 1993, **366**:704-707.
2. Quelle DE, Zindy F, Ashmun RA, Sherr CJ: Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. *Cell* 1995, **83**:993-1000.
3. Gil J, Peters G: Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. *Nat Rev Mol Cell Biol* 2006, **7**:667-677.
4. Kim WY, Sharpless NE: The regulation of INK4a/ARF in cancer and aging. *Cell* 2006, **127**:265-275.
5. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. *Nature* 1994, **368**:753-756.
6. Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennett WP, Forrester K, Gerwin B, Serrano M, Beach DH: Mutations and altered expression of p16INK4 in human cancer. *Proc Natl Acad Sci USA* 1994, **91**:11045-11049.
7. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavitian SV, Stockert E, Day RS, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of any tumor types. *Science* 1994, **264**:436-40.
8. Ruas M, Peters G: The p16<sup>INK4a</sup>/CDKN2A tumor suppressor and its relatives. *Biochim Biophys Acta* 1998, **1378**:F115-77.
9. Rocco JW, Sidransky D: p16<sup>MTS-1/CDKN2/INK4a</sup> in cancer progression. *Exp Cell Res* 2001, **264**:42-55.
10. Ortega S, Malumbres M, Barbacid M: Cyclin D-dependent kinases, INK4 inhibitors and cancer. *Biochim Biophys Acta* 2002, **1602**:73-87.
11. Hara E, Smith R, Parry D, Tahara H, Stone S, Peters G: Regulation of p16<sup>CDKN2</sup> expression and its implications for cell immortalization and senescence. *Mol Cell Biol* 1996, **16**:859-867.
12. Palmero I, McConnell B, Parry D, Brookes S, Hara E, Bates S, Jat P, Peters G: Accumulation of p16INK4a in mouse fibroblasts as a function of replicative senescence and not of retinoblastoma gene status. *Oncogene* 1997, **15**:495-503.
13. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW: Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16<sup>INK4a</sup>. *Cell* 1997, **88**:593-602.
14. Serrano M, Blasco MA: Putting the stress on senescence. *Curr Opin Cell Biol* 2001, **13**:748-53.
15. Ohtani N, Zebedee Z, Huot TJ, Stinson JA, Sugimoto M, Ohashi Y, Sharrocks AD, Peters G, Hara E: Opposing effects of Ets and Id proteins on p16<sup>INK4a</sup> expression during cellular senescence. *Nature* 2001, **409**:1067-1070.
16. Collado M, Blasco MA, Serrano M: Cellular senescence in cancer and aging. *Cell* 2007, **130**:223-233.
17. McConnell BB, Starborg M, Brookes S, Peters G: Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human diploid fibroblasts. *Curr Biol* 1998, **8**:351-354.
18. Ohtani N, Mann DJ, Hara E: Cellular senescence Its role in tumor suppression and aging. *Cancer Science* 2009, **100**:792-797.
19. Takahashi A, Ohtani N, Yamakoshi K, Iida S, Tahara H, Nakayama K, Nakayama KI, Ide T, Saya H, Hara E: Mitogenic signalling and the p16<sup>INK4a</sup>-Rb pathway cooperate to enforce irreversible cellular senescence. *Nat Cell Biol* 2006, **8**:1291-1297.
20. Zindy F, Quelle DE, Roussel MF, Sherr CJ: Expression of the p16<sup>INK4a</sup> tumor suppressor versus other INK4 family members during mouse development and aging. *Oncogene* 1997, **15**:203-211.
21. Ince TA, Richardson AL, Bell GW, Saitoh M, Godar S, Karnoub AE, Iglehart JD, Weinberg RA: Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. *Cancer Cell* 2007, **12**:160-170.
22. Ramirez RD, Morales CP, Herbert BS, Rohde JM, Passons C, Shay JW, Wright WE: Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions. *Genes Dev* 2001, **15**:398-403.
23. Benanti JA, Galloway DA: Normal human fibroblasts are resistant to RAS-induced senescence. *Mol Cell Biol* 2004, **24**:2842-2852.

24. Sharpless NE, Bardeesy N, Lee KH, Carrasco D, Castrillon DH, Aguirre AJ, Wu EA, Horner JW, DePinho RA: **Loss of p16<sup>Ink4a</sup> with retention of p19<sup>Arf</sup> predisposes mice to tumorigenesis.** *Nature* 2001, **413**:86-91.
25. Krimpenfort P, Quon KC, Mooi WJ, Loonstra A, Berns A: **Loss of p16<sup>Ink4a</sup> confers susceptibility to metastatic melanoma in mice.** *Nature* 2001, **413**:83-86.
26. Krimpenfort P, Ijpenberg A, Song JY, Valk van der M, Nawijn M, Zevenhoven J, Berns A: **p15<sup>Ink4b</sup> is a critical tumour suppressor in the absence of p16<sup>Ink4a</sup>.** *Nature* 2007, **448**:943-946.
27. Ramsey MR, Krishnamurthy J, Pei XH, Torrice C, Lin W, Carrasco DR, Ligon KL, Xiong Y, Sharpless NE: **Expression of p16<sup>Ink4a</sup> compensates for p18<sup>Ink4c</sup> loss in cyclin-dependent kinase 4/6-dependent tumors and tissues.** *Cancer Res* 2007, **67**:4732-4741.
28. Wiedemeyer R, Brennan C, Heffernan TP, Xiao Y, Mahoney J, Protopopov A, Zheng H, Bignell G, Furnari F, Cavenee WK, Hahn WC, Ichimura K, Collins VP, Chu GC, Stratton MR, Ligon KL, Futreal PA, Chin L: **Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development.** *Cancer Cell* 2008, **13**:355-364.
29. Contag PR, Olomu IN, Stevenson DK, Contag CH: **Bioluminescent indicators in living mammals.** *Nat Med* 1998, **4**:245-247.
30. Dothager RS, Flentje K, Moss B, Pan MH, Kesarwala A, Piwnicka-Worms D: **Advances in bioluminescence imaging of live animal models.** *Curr Opin Biotechnol* 2009, **20**:45-53.
31. Ohtani N, Imamura Y, Yamakoshi K, Hirota F, Nakayama R, Kubo Y, Ishimaru N, Takahashi A, Hirao A, Shimizu T, Mann DJ, Saya H, Hayashi Y, Arase S, Matsumoto M, Kazuki N, Hara E: **Visualizing the dynamics of p21<sup>Waf1/Cip1</sup> cyclin-dependent kinase inhibitor expression in living animals.** *Proc Natl Acad Sci USA* 2007, **104**:15034-15039.
32. Uhrbom L, Nerio E, Holland EC: **Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model.** *Nat Med* 2004, **10**:1257-1260.
33. Zhang GJ, Safran M, Wei W, Sorensen E, Lassota P, Zhelev N, Neuberger DS, Shapiro G, Kaelin WG Jr: **Bioluminescent imaging of Cdk2 inhibition in vivo.** *Nat Med* 2004, **10**:643-648.
34. Li F, Sonveaux P, Rabbani ZN, Liu S, Yan B, Huang Q, Vujaskovic Z, Dewhirst MW, Li CY: **Regulation of HIF-1alpha stability through S-nitrosylation.** *Mol Cell* 2007, **26**:63-74.
35. Vooijs M, Jonkers J, Lyons S, Berns A: **Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice.** *Cancer Res* 2002, **62**:1862-1867.
36. Paulmurugan R, Umezawa Y, Gambhir SS: **Noninvasive imaging of protein-protein interactions in living subjects by using reporter protein complementation and reconstitution strategies.** *Proc Natl Acad Sci USA* 2002, **99**:15608-15613.
37. Yamakoshi K, Takahashi A, Hirota F, Nakayama R, Ishimaru N, Kubo Y, Mann DJ, Ohmura M, Hirao A, Saya H, Arase S, Hayashi Y, Nakao K, Matsumoto M, Ohtani N, Hara E: **Real-time in vivo imaging of p16<sup>Ink4a</sup> reveals cross talk with p53.** *J Cell Biol* 2009, **186**:393-407.
38. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M: **The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the Ink4a locus.** *Nature* 1999, **397**:164-168.
39. Kotake Y, Cao R, Viatour P, Sage J, Zhang Y, Xiong Y: **pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16<sup>Ink4a</sup> tumor suppressor gene.** *Genes Dev* 2007, **21**:49-54.
40. Krishnamurthy J, Torrice C, Ramsey MR, Kovalev GI, Al-Regaiey K, Su L, Sharpless NE: **Ink4a/Arf expression is a biomarker of aging.** *J Clin Invest* 2004, **114**:1299-1307.
41. Herbig U, Ferreira M, Condel L, Carey D, Sedivy JM: **Cellular senescence in aging primates.** *Science* 2006, **311**:1257.
42. Ressler S, Bartkova J, Niederegger H, Bartek J, Scharffetter-Kochanek K, Jansen-Dürr P, Wlaschek M: **p16<sup>Ink4a</sup> is a robust in vivo biomarker of cellular aging in human skin.** *Aging Cell* 2006, **5**:379-389.
43. Tsygankov D, Liu Y, Sanoff HK, Sharpless NE, Elston TC: **A quantitative model for age-dependent expression of the p16<sup>Ink4a</sup> tumor suppressor.** *Proc Natl Acad Sci USA* 2009, **106**:16562-16567.
44. Campisi J: **Senescent cells tumor suppression and organismal aging good citizens bad neighbors.** *Cell* 2005, **120**:513-522.
45. Quintanilla M, Brown K, Ramsden M, Balmain A: **Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis.** *Nature* 1986, **322**:78-80.
46. Kemp CJ: **Multistep skin cancer in mice as a model to study the evolution of cancer cells.** *Semin Cancer Biol* 2005, **15**:460-473.
47. Sharpless NE, Ramsey MR, Balasubramanian P, Castrillon DH, DePinho RA: **The differential impact of p16<sup>Ink4a</sup> or p19<sup>Arf</sup> deficiency on cell growth and tumorigenesis.** *Oncogene* 2004, **23**:379-385.
48. Estève PO, Chin HG, Smallwood A, Feehery GR, Gangisetty O, Karpf AR, Carey MF, Pradhan S: **Direct interaction between DNMT1 and G9a coordinates DNA and histone methylation during replication.** *Genes Dev* 2006, **20**:3089-103.
49. MacLeod AR, Rouleau J, Szyf M: **Regulation of DNA methylation by the Ras signaling pathway.** *J Biol Chem* 1995, **270**:11327-11337.
50. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, Vassiliou LV, Kolettas E, Niforou K, Zoumpoulis VC, Takaoka M, Nakagawa H, Tort F, Fugger K, Johansson F, Sehested M, Andersen CL, Dyrskjot L, Ørntoft T, Lukas J, Kittas C, Helleday T, Halazonetis TD, Bartek J, Gorgoulis VG: **Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints.** *Nature* 2006, **444**:633-637.
51. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, Schurra C, Garre' M, Nuciforo PG, Bensimon A, Maestro R, Pelicci PG, d'Adda di Fagagna F: **Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication.** *Nature* 2006, **444**:638-642.
52. Mallette FA, Gaumont-Leclerc MF, Ferbeyre G: **The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence.** *Genes Dev* 2007, **21**:43-48.
53. McCabe MT, Davis JN, Day ML: **Regulation of DNA methyltransferase 1 by the pRb/E2F1 pathway.** *Cancer Res* 2005, **65**(9):3624-3632.
54. Robert MF, Morin S, Beaulieu N, Gauthier F, Chute IC, Barsalou A, MacLeod AR: **DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells.** *Nat Genet* 2003, **33**:61-65.
55. Vousden KH, Lane DP: **p53 in health and disease.** *Nat Rev Mol Cell Biol* 2007, **8**:275-283.
56. Riley T, Sontag E, Chen P, Levine A: **Transcriptional control of human p53-regulated genes.** *Nat Rev Mol Cell Biol* 2008, **9**:402-412.
57. Leong WF, Chau JF, Li B: **p53 Deficiency leads to compensatory up-regulation of p16<sup>Ink4a</sup>.** *Mol Cancer Res* 2009, **7**:354-360.
58. Zhang D, Shimizu T, Araki N, Hirota T, Yoshie M, Ogawa K, Nakagata N, Takeya M, Saya H: **Aurora A overexpression induces cellular senescence in mammary gland hyperplastic tumors developed in p53-deficient mice.** *Oncogene* 2008, **27**:4305-4314.
59. Jacobs JJ, de Lange T: **Significant role for p16<sup>Ink4a</sup> in p53-independent telomere-directed senescence.** *Curr Biol* 2004, **14**:2302-2308.
60. Jacobs JJ, de Lange T: **p16<sup>Ink4a</sup> as a second effector of the telomere damage pathway.** *Cell Cycle* 2005, **4**:1364-1368.
61. Sharpless NE, Alson S, Chan S, Silver DP, Castrillon DH, DePinho RA: **p16<sup>Ink4a</sup> and p53 deficiency cooperate in tumorigenesis.** *Cancer Res* 2002, **62**:2761-2765.
62. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA, Van Pelt CS, Lozano G: **The inherent instability of mutant p53 is alleviated by Mdm2 or p16<sup>Ink4a</sup> loss.** *Genes Dev* 2008, **22**:1337-1344.
63. Malumbres M, Barbacid M: **To cycle or not to cycle a critical decision in cancer.** *Nat Rev Cancer* 2001, **1**:222-231.
64. Passequé E, Wagner EF: **JunB suppresses cell proliferation by transcriptional activation of p16<sup>Ink4a</sup> expression.** *EMBO J* 2000, **19**:2969-2979.
65. Ohtani N, Brennan P, Gaubatz S, Sanij E, Hertzog P, Wolvetang E, Ghysdael J, Rowe M, Hara E: **Epstein-Barr virus LMP1 blocks p16<sup>Ink4a</sup>-RB pathway by promoting nuclear export of E2F4/5.** *J Cell Biol* 2003, **162**:173-83, Epub 2003.
66. Gonzalez S, Klatt P, Delgado S, Conde E, Lopez-Rios F, Sanchez-Céspedes M, Mendez J, Antequera F, Serrano M: **Oncogenic activity of Cdc6 through repression of the INK4/ARF locus.** *Nature* 2006, **440**:702-706.
67. Bracken AP, Kleine-Kohlbrecher D, Dietrich N, Pasini D, Gargiulo G, Beekman C, Theilgaard-Mönch K, Minucci S, Porse BT, Marine JC, Hansen KH, Helin K: **The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells.** *Genes Dev* 2007, **21**:525-530.
68. Baker DJ, Perez-Terzic C, Jin F, Pitel K, Niederländer NJ, Jeganathan K, Yamada S, Reyes S, Rowe L, Hiddinga HJ, Eberhardt NL, Terzic A, van Deursen JM: **Opposing roles for p16<sup>Ink4a</sup> and p19<sup>Arf</sup> in senescence and ageing caused by BubR1 insufficiency.** *Nat Cell Biol* 2008, **10**:825-836.

69. Tzatsos A, Pfau R, Kampranis SC, Tsiichlis PN: **Ndy1/KDM2B immortalizes mouse embryonic fibroblasts by repressing the Ink4a/Arf locus.** *Proc Natl Acad Sci USA* 2009, **106**:2641-6.
70. Witcher M, Emerson BM: **Epigenetic silencing of the p16<sup>INK4a</sup> tumor suppressor is associated with loss of CTCF binding and a chromatin boundary.** *Mol Cell* 2009, **34**:271-284.
71. Agger K, Cloos PA, Rudkjaer L, Williams K, Andersen G, Christensen J, Helin K: **The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence.** *Genes Dev* 2009, **23**:1171-6.
72. Barradas M, Anderton E, Acosta JC, Li S, Banito A, Rodriguez-Niedenführ M, Maertens G, Banck M, Zhou MM, Walsh MJ, Peters G, Gil J: **Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS.** *Genes Dev* 2009, **23**:1177-1182.
73. Kia SK, Gorski MM, Giannakopoulos S, Verrijzer CP: **SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus.** *Mol Cell Biol* 2008, **28**:3457-3464.
74. Wong ES, Le Guezennec X, Demidov ON, Marshall NT, Wang ST, Krishnamurthy J, Sharpless NE, Dunn NR, Bulavin DV: **p38MAPK controls expression of multiple cell cycle inhibitors and islet proliferation with advancing age.** *Dev Cell* 2009, **17**:142-149.

doi:10.1186/1747-1028-5-1

**Cite this article as:** Ohtani *et al.*: Real-time *in vivo* imaging of p16<sup>INK4a</sup> gene expression: a new approach to study senescence stress signaling in living animals. *Cell Division* 2010 **5**:1.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

